Literature DB >> 6775594

Pharmacokinetic studies with dibekacin, a new aminoglycoside, after intravenous and intramuscular administration to human volunteers.

M Goto, M Sugiyama, T Ishizaki.   

Abstract

The pharmacokinetics of dibekacin, a new aminoglycoside antibiotic, was studied in volunteers given the same dose (100 mg) intramuscularly on two separate occasions and intravenously at two different rates of infusion. The kinetic parameters (t 1/2, 2.24 h, and Vd, 0.136 liter/kg, as the overall mean) observed after intramuscular administration appear to be compatible with those of other aminoglycosides and fairly reproducible within the same individuals. Dibekacin was rapidly absorbed (tmax, 0.84 h), yielding a peak level of 10.4 microgram/ml after the 100-mg intramuscular dose. After the 30- or 60-min infusion, the concentrations of dibekacin in serum fell bi-exponentially, giving an elimination half-life (t 1/2 beta) of 2.50 to 2.88 h. The highest serum levels after th 30- and 60-min infusions were 15.2 +/- 0.9 and 12.1 +/- 1.8 microgram/ml, respectively. Serum levels at 6 h after completion of infusions were 1.9 +/- 0.3 and 1.7 +/- 0.4 microgram/ml, respectively.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6775594      PMCID: PMC284008          DOI: 10.1128/AAC.18.3.372

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Pharmacokinetics and dosing of antimicrobial agents in renal impairment. I.

Authors:  E A Jackson; D C McLeod
Journal:  Am J Hosp Pharm       Date:  1974-01

2.  Pharmacologic studies on tobramycin and comparison with gentamicin.

Authors:  B R Meyers; S Z Hirschman
Journal:  J Clin Pharmacol New Drugs       Date:  1972 Aug-Sep

3.  Comparative pharmacokinetics of tobramycin and gentamicin.

Authors:  C Regamey; R C Gordon; W M Kirby
Journal:  Clin Pharmacol Ther       Date:  1973 May-Jun       Impact factor: 6.875

4.  Clinical pharmacology of tobramycin.

Authors:  N Horikoshi; M Valdivieso; G P Bodey
Journal:  Am J Med Sci       Date:  1973-12       Impact factor: 2.378

5.  Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

6.  Gentamicin sulfate distribution in body fluids.

Authors:  V Rodriguez; D Stewart; G P Bodey
Journal:  Clin Pharmacol Ther       Date:  1970 Mar-Apr       Impact factor: 6.875

7.  Relation between dose and levels of gentamicin in blood.

Authors:  R E Winters; K D Litwack; W L Hewitt
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

8.  3',4'-dideoxy-kanamycin B active against kanamycin-resistant Escherichia coli and Pseudomonas aeruginosa.

Authors:  H Umezawa; S Umezawa; T Tsuchiya; Y Okazaki
Journal:  J Antibiot (Tokyo)       Date:  1971-07       Impact factor: 2.649

9.  Pharmacokinetic studies of tobramycin and gentamicin.

Authors:  V K Simon; E U Mösinger; V Malerczy
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191

10.  Comparative pharmacokinetics of BB-K8 and kanamycin in dogs and humans.

Authors:  B E Cabana; J G Taggart
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191

View more
  2 in total

1.  Tobramycin inactivation by carbenicillin, ticarcillin, and piperacillin.

Authors:  H Konishi; M Goto; Y Nakamoto; I Yamamoto; H Yamashina
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

2.  Fosfomycin kinetics after intravenous and oral administration to human volunteers.

Authors:  M Goto; M Sugiyama; S Nakajima; H Yamashina
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.